|
Workshop Name |
Speakers |
Date |
Major Sponsor |
|
Modern NMR technologies for trace compound analysis: metabolites,
impurities, and degradants |
Joe Pease (Roche), Raju Subramanian (Amgen), Smriti Khera (Amgen) |
05/14/2010 |
XenoBiotic
Laboratories |
|
Solid Dosage Forms: Theory,
Formulation Strategies & Case Studies for Clinical Developments
(co-organized
with University of the Pacific) |
B.R. Jasti, X. Li, R. Nyshadham, R. Mahalingam |
06/10/2010 |
|
|
PK Modeling |
Harvey
Wong, PhD (Genentech); Matt Wright, PhD (Gilead); Natilie Hosea, PhD
(Pfizer); Jane Kenny
Genentech) |
08/02/2010 |
BD
Biosciences |
|
Statistics fundamentals |
|
2010 |
|
|
Species differences and the impact on DMPK properties |
|
2010 |
|
|
Case studies: trouble-shooting high clerarance and poor bioavailability |
|
2010 |
|
|
Excel for Scientists |
|
2010 |
|
|
Preclinical Mass Balance and Metabolite Profiling Studies |
|
2010 |
|
|
Human ADME Studies: Mass Balance and Metabolite Profiling |
|
2010 |
|
|
Workshop Name |
Speakers |
Date |
Major Sponsor |
|
Drug Transporters: Interpretation
and Application of the International Transporter Consortium Whitepaper and
Draft FDA Guidance |
Joseph Polli (GSK), Caroline Lee (Pfizer), Harma Ellens (GSK), Xiaoyan Chu
(Merck) |
04/19/2010 |
Qualyst, Inc. |
|
ADME Sciences as Applied to
Assessing Safety Testing (MIST) |
Scott Obach (Pfizer) |
03/10/2010 |
XenoBiotic Laboratories |
|
Non-clinical Drug Safety and Toxicology: From Discovery to Market with Large
Molecule Drugs |
Ben Marafino, Jr. (SMC),
Kathleen Meyer (XOMA) |
02/22/2010 |
Pacific Biolabs |
|
Introductory LC/MS |
Jack
Henion |
01/12/2010 |
Agilent
Technologies |
|
Advanced
LC/MS Practices |
Jack
Henion |
01/13/2010 |
Alturas
Analytics; BASi |
|
Advances in Analytical and Automation Technologies for DMPK |
Patrick Rudewicz (Genentech), Jane Huang (Roche), Ji Ma (Amgen), Sheerin
Shahidi (Genentech), John Laycock (Amgen) |
12/8/2009 |
Advanced
Chemistry Development, Inc., (ACD/Labs) |
|
Non-clinical Drug Safety and Toxicology: From Discovery to Market with Small
Molecule Drugs |
Ben Marafino, Jr. (SMC),
Kathleen Meyer (XOMA) |
10/26/2009 |
Pacific BioLabs |
|
Dug metabolite identification |
Bill Fitch (Roche), Shichang Miao (ChemoCentryx), Deepak Dalvie (Pfizer) |
9/30/2009 |
Thermo |
|
Clinical Pharmacokinetics & Pharmacodynamics in Drug Development |
Graham Jang (Amgen), David Lau (Rigel),
Nelson “Shasha” Jumbe (Roche) |
9/8/2009 |
Applied Biosystems |
|
DMPK and Clinical Pharmacology Studies in IND and NDA Submissions:
Leveraging Regulation and Science in Clinical Drug Development and
Regulatory Decisions |
Derek Zhang (Frontage Laboratories), Deanna
Kroetz (UCSF) |
8/17/2009 |
Cyprotex |
|
Pharmacokinetic profiles for large molecules |
Suhasini Iyer (Genentech), Jay Tibbitts (Genentech), Valerie Quarmby
(Genentech) |
4/28/2009 |
Tandem Labs |
|
HPLC for DMPK, Bioanalysis, and Analytical Development: Liquid
Chromatography Essentials, Best Practices, and Recent Developments. |
Michael Dong; Patrick Rudewicz (Genentech) |
3/26/2009 |
Alturas |
|
Preclinical Development & IND filing |
Tracy Chen (Depomed), Linval Depass (Duret), Jeff Etter (Celegen), Jim Wei (Medpace) |
2/26/2009 |
Absorption Systems, BD, Avantium |
|
Physicochemical properties and Preformulation Support for PK Studies |
Shelley Rabel Reiley (consultant), Minli Xie (Genentech) |
1/26/2009 |
Avantium |
|
Bioanalytical method validation and GLP bioanalysis |
Danlin Wu (Roche), Mark Rose (Amgen), Patrick Rudewicz (Genentech), Ago
Ahene (Roche) |
11/24/2008 |
BRI; Alta, Alturas |
|
Applied Pharmacokinetics |
George Tonn (Elan), Harvey Wong (Genentech) |
10/30/2008 |
BRI |
|
Overcoming high clearance and poor bioavailability |
David Lau (J&J); Matthew Wright (Gilead), Tracy Chen (Celgene) |
9/10/2008 |
ABI |
|
Drug metabolism and drug metabolizing enzymes |
Cyrus Khojasteh (Genentech), Kirk Henne (Amgen), Deepak Dalvie (Pfizer) |
6/27/2008 |
Waters |
|
Drug Transporters |
Jeff Silverman (Sunesis), Les Benet (UCSF), Kathy Giacommini (UCSF), Joe
Ware (Genentech) |
4/8/2008 |
BD |
|
Prediction of in vivo PK profiles from in vitro data |
Jae Chang, Phil Worboys (Roche) |
2/5/2008 |
BRI |
|
Drug-drug interaction |
Magang Shou (Amgen); Simon Wong (Amgen), Adrian Fretland (Roche) |
12/11/2007 |
Phenomenex |
|
in vitro ADME techniques and assays |
Tim Carlson (Amgen SSF); Bernard Murray (Gilead), Mark Grillo (Amgen) |
9/27/2007 |
ANALIZA |
|
DMPK Regulatory Requirements and Interactions with FDA |
Parnian Zia-Amirhosseini (Amgen), Stephen Gracon (Baxter) |
8/3/2007 |
Absorption Systems |